Duncan I B, Jeans B
Can Med Assoc J. 1965 Sep 25;93(13):685-91.
The usefulness of the new antibiotic, lincomycin, was assessed on both bacteriological and clinical grounds. Of 3200 strains of staphylococci isolated from clinical material, only 40 were resistant to lincomycin. These 40 were all of the same phage type and in fact almost all represented different isolations of the same staphylococcus which had spread to cross-infect various patients. Sixteen of 22 patients with staphylococcal infections, nine of 14 with pneumonia, 15 of 17 with acute exacerbations of bronchitis and two patients with other bacterial infections recovered completely with lincomycin therapy. The only side effect was diarrhea in four of the 42 patients given the drug by mouth. The place of lincomycin in therapeutics seems to be principally in the treatment of chronic osteomyelitis and, in patients allergic to the penicillins, in the treatment of staphylococcal, respiratory and other infections for which penicillin is usually employed.
从细菌学和临床角度对新型抗生素林可霉素的效用进行了评估。从临床材料中分离出的3200株葡萄球菌中,只有40株对林可霉素耐药。这40株均为同一噬菌体类型,实际上几乎都代表同一葡萄球菌的不同分离株,该葡萄球菌已传播并交叉感染了不同患者。22例葡萄球菌感染患者中有16例、14例肺炎患者中有9例、17例急性支气管炎加重患者中有15例以及2例其他细菌感染患者接受林可霉素治疗后完全康复。唯一的副作用是42例口服该药的患者中有4例出现腹泻。林可霉素在治疗学中的地位似乎主要在于治疗慢性骨髓炎,以及用于对青霉素过敏的患者,治疗通常使用青霉素的葡萄球菌感染、呼吸道感染和其他感染。